Related Experiment Video
Updated: Aug 11, 2025

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
Phosphodiesterases type 2, 3 and 4 promote vascular tone in mesenteric arteries from rats with heart failure
Liting Wang1, Fabien Hubert1, Sarah Idres1
1Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France.
Insights
In heart failure (HF), phosphodiesterase (PDE) 3 and 4 contribute to vasoconstriction in mesenteric arteries, unlike in the aorta. PDE2 also promotes contraction, a role preserved in HF.
Area of Science:
- Vascular Biology
- Cardiovascular Physiology
- Pharmacology
Background:
- Phosphodiesterases (PDE) types 3 and 4 hydrolyze cyclic adenosine monophosphate (cAMP), promoting vasoconstriction.
- In experimental heart failure (HF), PDE3's role in the aorta may render PDE4 redundant.
- The roles of PDE2, PDE3, and PDE4 in resistance vessels like mesenteric arteries during HF are not well understood.
Purpose of the Study:
- To investigate the function of PDE2, PDE3, and PDE4 in rat mesenteric arteries during experimental heart failure (HF).
- To determine the contribution of these PDE isoenzymes to vasoconstriction and vasodilation in both healthy and failing conditions.
Main Methods:
- Isolation of mesenteric arteries from rats with surgically induced HF or sham surgery.
- Utilized PDE inhibitors in enzymatic and isometric tension assays.
- Investigated the role of nitric oxide synthase (NOS) inhibition using L-NAME.
Main Results:
- In healthy arteries, PDE2 and PDE4, but not PDE3, facilitated contraction.
- In HF arteries, PDE2, PDE3, and PDE4 all contributed to contraction.
- PDE3 and PDE4 activities were reduced in HF mesenteric arteries, while PDE2 activity remained.
- PDE2 inhibition's effect was abolished by L-NAME, suggesting a link to NO synthase.
- PDE3 and PDE4 attenuated beta-adrenergic relaxation in both healthy and HF states.
Conclusions:
- Contrary to aortic findings, PDE3 and PDE4 equally contribute to mesenteric artery contraction in HF.
- PDE2 activity promotes contraction and is preserved in the context of HF.
- PDE2's role in contraction is linked to nitric oxide synthase activity.
Abstract:
Phosphodiesterases (PDE) type 3 and 4 promote vasoconstriction by hydrolysing cAMP. In experimental heart failure (HF), PDE3 makes PDE4 redundant in aorta, but it is not known if this occurs in resistance vessels, such as mesenteric artery. As PDE2 is increased in the failing myocardium, its possible role in the vasculature also needs to be addressed. Here, the function of PDE2, PDE3 and PDE4 in rat mesenteric arteries was characterized in experimental HF. Mesenteric arteries were isolated from rats sacrificed 22 weeks after surgical stenosis of the ascending aorta (HF), or Sham surgery. PDE inhibitors were used to probe isoenzyme contributions in enzymatic and isometric tension assays. PDE2 and PDE4 activities, but not PDE3 activity, facilitate contraction produced by the thromboxane analogue U46619 in Sham arteries, while in HF all three isoenzymes contribute to this response. NO synthase inhibition by L-NAME abolished the action of the PDE2 inhibitor. L-NAME eliminated the contribution of PDE4 in HF, but unmasked a contribution for PDE3 in Sham. PDE3 and PDE4 activities attenuated relaxant response to β-adrenergic stimulation in Sham and HF. PDE2 did not participate in cAMP or cGMP-mediated relaxant responses. PDE3 and PDE4 cAMP-hydrolysing activities were smaller in HF mesenteric arteries, while PDE2 activity was scarce in both groups. Endothelial cells and arterial myocytes displayed PDE2 immunolabelling. We highlight that, by contrast with previous observations in aorta, PDE4 participates equally as PDE3 in contracting mesenteric artery in HF. PDE2 activity emerges as a promoter of contractile response that is preserved in HF.
Related Concept Videos
Heart Failure II: Pathophysiology
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: β-Blockers

